PMVP Stock Summary and Trading Ideas (PMV Pharmaceuticals | NASDAQ:PMVP)

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

PMV Pharmaceuticals trades on the NASDAQ stock market under the symbol PMVP.

As of May 28, 2026, PMVP stock price declined to $1.19 with 464,561 million shares trading.

PMVP has a beta of 0.48, meaning it tends to be less sensitive to market movements. PMVP has a correlation of 0.01 to the broad based SPY ETF.

PMVP has a market cap of $63.46 million. This is considered a Micro Cap stock.

In the last 3 years, PMVP traded as high as $9.72 and as low as $.81.

The top ETF exchange traded funds that PMVP belongs to (by Net Assets): VTI, VXF, IWC, AVTM.

PMVP has outperformed the market in the last year with a return of +32.2%, while the SPY ETF gained +28.9%. However, in the most recent history, PMVP shares have underperformed the stock market with its stock returning -30.0% in the last 3 month period and -7.8% for the last 2 week period, while SPY has returned +10.3% and +1.7%, respectively.

PMVP support price is $1.15 and resistance is $1.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PMVP shares will trade within this expected range on the day.